AbbVie’s Rinvoq.com achieved the highest total traffic across branded rheumatoid arthritis (RA) patient sites in the US, with over 2.6 million visitors from February 2023 to January 2024. This was followed by AbbVie’s Humira.com (over 1 million visits). Overall, the highest proportion of traffic to top branded patient RA websites originated from direct sources, followed by organic. UCB’s Cimzia.com had the highest proportion of direct traffic (73%), followed by Pfizer’s Xeljanz.com (58%). Xeljanz.com was supported by the most paid SEO with over 6,900 keywords, closely followed by Rinvoq.com (6,693). Pfizer spent the most on DDA for Xeljanz.com, at approximately $6.6 million. DDA was also detected for Olumiant.com ($440K) and Cimzia.com ($350K).
Orenciahcp.com achieved the highest total traffic across RA patient sites in the US, with over 160,000 visitors from February 2023 to January 2024. This was followed by Rinvoqhcp.com with over 140K visitors. Overall, the highest proportion of traffic to branded RA websites for HCPs originated from organic sources, followed by direct and paid traffic. Enbrelpro.com was also supported by the most paid SEO at over 3,500 keywords, closely followed by Rinvoqhcp.com (2,799). Amgen spent the most on DDA for Enbrelpro.com, at approximately $23K. DDA was also detected for Rinvoqhcp.com ($1.5K).
In the US, few RA-specific unbranded resources were detected from pharma companies. Between February 2023 and January 2024, the highest traffic levels were achieved by AbbVie’s RA.com, with more than 32K views across the period. This was followed by Pfizer’s Arthritis.com with more than 10K views across the period.
AbbVie’s AbbVie-care.de achieved the highest total traffic across RA branded sites in the EUCAN, with over 400K visitors from February 2023 - January 2024. Between February 2023 and January 2024, Roche's Rhumatismes.net achieved the highest levels of traffic across unbranded sites in the EUCAN of approximately 150K total views across the period. There was no DDA detected across these sites.
Orenciahcp.com achieved the highest total traffic across RA patient sites in the US, with over 160,000 visitors from February 2023 to January 2024. This was followed by Rinvoqhcp.com with over 140K visitors. Overall, the highest proportion of traffic to branded RA websites for HCPs originated from organic sources, followed by direct and paid traffic. Enbrelpro.com was also supported by the most paid SEO at over 3,500 keywords, closely followed by Rinvoqhcp.com (2,799). Amgen spent the most on DDA for Enbrelpro.com, at approximately $23K. DDA was also detected for Rinvoqhcp.com ($1.5K).
In the US, few RA-specific unbranded resources were detected from pharma companies. Between February 2023 and January 2024, the highest traffic levels were achieved by AbbVie’s RA.com, with more than 32K views across the period. This was followed by Pfizer’s Arthritis.com with more than 10K views across the period.
AbbVie’s AbbVie-care.de achieved the highest total traffic across RA branded sites in the EUCAN, with over 400K visitors from February 2023 - January 2024. Between February 2023 and January 2024, Roche's Rhumatismes.net achieved the highest levels of traffic across unbranded sites in the EUCAN of approximately 150K total views across the period. There was no DDA detected across these sites.
Scope
- This report assesses key digital marketing metrics of pharma assets in RA including branded websites for patients and HCPs and unbranded sites.
- Metrics include website traffic volume, engagement, and source, DDA and paid SEO.
- Countries include the US and EUCAN.
Reasons to Buy
- Understand the digital marketing competitive landscape in RA, with a view of leading patient and HCP branded assets across different regions.
- See what tactics pharma companies are using to drive traffic to their RA branded assets for patient and HCPs, such as DDA and paid SEO.
- Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
- Compare top branded and unbranded assets for patients by how they address and support different patient needs.
Table of Contents
- Executive Summary
- US Branded Websites for Patients
- US Branded Websites for Physicians
- EUCAN Branded Websites
- EUCAN Unbranded Websites
- Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- UCB
- Pfizer
- Amgen
- Roche
